Advertisement
Advertisement
DNLI
Denali Therapeutics Inc. Common Stock
20.07
USDSponsored
+0.35
+1.77%
Nov 06, 15:59 UTC -5
Closed
After-Market
20.06
-0.01
-0.05%
Denali Therapeutics Inc. Common Stock (DNLI) Earnings
DNLI Earnings Reports
Positive Surprise Ratio
DNLI beat 17 of 36 last estimates.
47%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$23.11M
/-$0.64
Implied change from Q3 26 (Revenue/ EPS)
+29.99%
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/-12.33%
Denali Therapeutics Inc. Common Stock earnings per share and revenue
On Nov 03, 2026, DNLI reported earnings of -0.64 USD per share (EPS) for Q3 26, missing the estimate of -0.54 USD, resulting in a -17.95% surprise. Revenue reached 17.78 million, compared to an expected 10.87 million, with a 63.57% difference. The market reacted with a +7.76% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 9 analysts forecast an EPS of -0.64 USD, with revenue projected to reach 23.11 million USD, implying an increase of 0.00% EPS, and increase of 29.99% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
FAQ
What were Denali Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Denali Therapeutics Inc. Common Stock reported EPS of -$0.64, missing estimates by -17.95%, and revenue of $17.78M, 63.57% above expectations.
How did the market react to Denali Therapeutics Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 7.76%, changed from $19.45 before the earnings release to $20.96 the day after.
When is Denali Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Denali Therapeutics Inc. Common Stock's next earnings report?
Based on 9
analysts, Denali Therapeutics Inc. Common Stock is expected to report EPS of -$0.64 and revenue of $23.11M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.